Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque...

Area of Science:

• Cardiovascular Research
• Vascular Biology
• Translational Medicine

Background:

• Angiogenesis in atherosclerotic plaques contributes to progression by promoting leakage of red blood cells and inflammatory mediators.
• Accumulation of cholesterol from leaked red blood cells can enlarge necrotic cores, destabilizing plaques.
• Immature plaque neovasculature is a key factor in atherosclerotic plaque vulnerability.

Purpose of the Study:

• To propose antiangiogenic therapy as a novel strategy to stabilize vulnerable atherosclerotic plaques.
• To investigate the potential of pruning and normalizing intraplaque neovasculature to prevent plaque progression.
• To explore the application of antiangiogenic agents, similar to those used in cancer therapy, for cardiovascular disease prevention.

Main Methods:

• The study proposes a therapeutic approach based on existing knowledge of antiangiogenic agents.
• It extrapolates the mechanism of tumor vessel normalization to intraplaque neovasculature.
• The approach leverages vascular endothelial growth factor (VEGF) antagonists as a potential therapeutic agent.

Main Results:

• Antiangiogenic therapy is hypothesized to prune and normalize intraplaque vessels, reducing hemorrhage.
• This normalization is expected to limit necrotic core expansion and luminal narrowing.
• The proposed mechanism aims to decrease plaque inflammation and overall vulnerability.

Conclusions:

• Antiangiogenic therapy offers a novel strategy for stabilizing rupture-prone atherosclerotic plaques.
• By normalizing intraplaque neovasculature, this approach may prevent plaque progression and associated cardiovascular events.
• This therapeutic avenue could enhance preventive measures against myocardial infarction, stroke, and sudden cardiac death.